Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 10, 2012REPRISE II Study Results Expected to Support CE Mark and Other Regulatory Filings
Boston Scientific (NYSE: BSX) has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus™...
-
Oct 9, 2012Victory™ guidewires are designed to facilitate crossing of resistant lesions
Boston Scientific Corporation (NYSE: BSX) has begun the United States and European launch of its Victory™ guidewire, designed to facilitate crossing...
-
Oct 8, 2012Pending Addition of Next Generation Mapping and Navigation System Would Expand Company Portfolio into Complex Electrophysiology Procedures
Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire privately-held Rhythmia Medical, Inc., a developer of...
-
Oct 8, 2012
Boston Scientific Corporation (NYSE: BSX) will webcast its third-quarter 2012 financial results conference call on Thursday, October 18th, at 8:00 a.m....
-
Oct 3, 2012These Disorders Affect Nearly 30 Million American Women; New Research Shows High Prevalence of Patients Not Understanding Their Treatment Options
Boston Scientific Corporation (NYSE: BSX) is a founding member of the Pelvic Floor Disorders (PFD) Alliance, a first-of-its-kind partnership formed to...
-
Oct 2, 2012S-ICD System is the World's First and Only Commercially Available Completely Subcutaneous Implantable Defibrillator
To view the multimedia assets associated with this release, please click:...
-
Sep 28, 2012S-ICD System is the World's First and Only Commercially Available Completely Subcutaneous Implantable Defibrillator
The U.S. Food and Drug Administration has granted Boston Scientific Corporation (NYSE: BSX) regulatory approval for its S-ICD® System, the world's...
-
Sep 28, 2012
Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for use of its Vercise™ Deep Brain Stimulation (DBS) System for the treatment...
-
Sep 27, 2012Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance for the Emerge™ Percutaneous Transluminal...
-
Sep 24, 2012RELIANCE® 4-FRONT™ Lead Designed to Streamline Surgical Procedure for Treatment of Heart Failure and Sudden Cardiac Arrest
Boston Scientific Corporation (NYSE: BSX) has received regulatory approval to market the RELIANCE® 4-FRONT™ lead, its next generation implantable...